Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLA478 SAD in Healthy Volunteers
NCT07240675Phase 1Recruiting
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KLA478 in Parkinson's disease (PD) (4 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoint: Incidence and severity of adverse events. Started Nov 2025; status: recruiting.
02
Drugs
KLA478
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07240675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240675.